Dupilumab therapy in children aged 2-12?years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study

被引：8
|
作者：
Zhou, Bingjing [1 ,2 ,3 ]
Peng, Cong [1 ,2 ,3 ]
Cao, Qiaozhi [1 ,2 ,3 ]
Wang, Jiayi [1 ,2 ,3 ]
Chen, Xiang [1 ,2 ,3 ]
Li, Jie [1 ,2 ,3 ]
机构：
[1] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 38卷 / 01期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1111/jdv.19409
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E35 / E38
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Simpson, E. L.
    Siegfried, E. C.
    Cork, M. J.
    Wollenberg, A.
    Arkwright, P. D.
    Soong, W.
    Gonzalez, M. E.
    Schneider, L. C.
    Sidbury, R.
    Lockshin, B.
    Wang, Z.
    Mannent, L. P.
    Amin, N.
    Sun, Y.
    Laws, E.
    Akinlade, B.
    Kosloski, M. P.
    Dubost-Brama, A.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E173 - E173
  • [22] Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
    Yang, Dan-Yang
    Li, Li
    Lu, Tao
    Jing, Wen-Wen
    Liu, Xin
    Li, Xiao-Li
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2023, 315 (03) : 467 - 472
  • [23] Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study
    Dan-Yang Yang
    Li Li
    Tao Lu
    Wen-Wen Jing
    Xin Liu
    Xiao-Li Li
    Archives of Dermatological Research, 2023, 315 : 467 - 472
  • [24] Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
    Baselga, Eulalia
    Murashkin, Nikolay
    Sung, Myong Soon
    Lee, Lara Wine
    Liu, Chunyuan
    Bates, Lauren
    Zhang, Annie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB200 - AB200
  • [25] Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis enrolled in the PEDISTAD Observational Study
    Baselga, E.
    Murashkin, N.
    Sung, M. S.
    Lee, L. W.
    Liu, C.
    Bates, L.
    Zhang, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 15 - 15
  • [26] Treatment outcomes for up to 2 years in patients aged <12 years with inadequately controlled moderate-to-severe atopic dermatitis: Real-world data from PEDISTAD
    Paller, Amy S.
    Murrell, Dedee F.
    Katelaris, Connie S.
    de Bruin-Weller, Marjolein
    Marcoux, Danielle
    Baselga, Eulalia
    de Carvalho, Vania Oliveira
    Ardusso, Ledit R. F.
    Toledo-Bahena, Mirna
    Gupta, Rajan
    Ardeleanu, Marius
    Zhang, Annie
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 14 - 14
  • [27] Dupilumab reduces atopic dermatitis lesion severity and extent in children <12 years of age with moderate-to-severe AD: interim results from the PEDISTAD real-world registry
    Lee, Lara Wine
    Irvine, Alan D.
    Ramien, Michele
    Marcoux, Danielle
    Baselga, Eulalia
    de Graaf, Marlies
    Antila, Martti
    Rosario Filho, Nelson A.
    Lara-Corrales, Irene
    Joyce, Joel C.
    Gupta, Rajan
    Redman, Patrick
    Zhang, Annie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [28] Dupilumab provides improvement in sleep in children aged ≥ 6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
    Paller, A.
    Wollenberg, A.
    Simpson, E.
    Beck, L.
    Hong, C-H
    Marcoux, D.
    Chen, Z.
    Levit, N.
    Bansal, A.
    Rossi, A.
    Chao, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 : 57 - 58
  • [29] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
    Parker, Jennifer J.
    Sugarman, Jeffrey L.
    Silverberg, Nanette B.
    Gonzalez, Mercedes Elena
    Ramien, Michele L.
    Teng, Joyce M. C.
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
  • [30] Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study
    Keow, Samantha
    Abu-Hilal, Mohannad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 734 - 735
12345